Theravance Biopharma Inc. (TBPH)
8.64
0.11 (1.29%)
At close: Jan 15, 2025, 3:59 PM
8.61
-0.35%
After-hours Jan 15, 2025, 04:00 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Net Income | -55.19M | -92.82M | -199.43M | -278.02M | -236.46M | -215.52M | -285.40M | -190.67M | -182.22M | -237.04M | -156.28M | -9.57M | -109.33M |
| Depreciation & Amortization | 4.26M | 7.02M | 9.71M | 9.06M | 6.21M | 3.17M | 4.03M | 3.12M | 2.99M | 2.66M | 2.65M | 3.25M | 3.84M |
| Stock-Based Compensation | 25.37M | 39.73M | 62.06M | 62.98M | 60.45M | 51.31M | 49.15M | 41.17M | 54.05M | 43.23M | 22.48M | 21.32M | n/a |
| Other Working Capital | -8.35M | 46.68M | -11.46M | -26.72M | -31.25M | 55.85M | 27.54M | 65.27M | -45.90M | 15.57M | 11.36M | -125.24M | -8.17M |
| Other Non-Cash Items | 3.70M | -183.28M | 3.86M | -20.43M | -23.01M | -43.00K | 10.00K | 182.00K | -8.06M | 3.22M | 20.00K | 196.00K | 23.91M |
| Deferred Income Tax | 3.21M | n/a | -44.48M | 15.46M | n/a | -11.21M | 8.74M | 282.00K | 2.17M | n/a | n/a | n/a | n/a |
| Change in Working Capital | -8.34M | 42.35M | -39.58M | -39.46M | -45.40M | 59.43M | 22.43M | 46.93M | -37.78M | 12.77M | 10.18M | -134.30M | -1.84M |
| Operating Cash Flow | -27.00M | -186.99M | -207.86M | -250.40M | -238.20M | -112.87M | -201.05M | -98.99M | -168.86M | -175.16M | -120.96M | -119.11M | -83.43M |
| Capital Expenditures | -2.49M | -572.00K | -3.41M | -6.62M | -3.18M | -7.24M | -2.41M | -2.13M | -2.65M | -3.11M | -2.73M | -2.59M | -3.63M |
| Acquisitions | n/a | 4.58M | 6.00K | 64.00K | 5.00M | 20.00M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | -134.53M | -103.14M | -158.31M | -401.99M | -423.90M | -183.26M | -288.79M | -237.57M | -73.01M | -168.89M | n/a | n/a | n/a |
| Sales Maturities Of Investments | 102.81M | 158.02M | 286.20M | 419.26M | 339.02M | 347.19M | 234.86M | 91.47M | 186.70M | 66.44M | n/a | n/a | n/a |
| Other Investing Acitivies | 1.51M | 1.10B | 127.90M | 17.34M | 5.00K | 17.00K | -53.93M | -146.10M | 113.69M | -693.00K | 100.00K | 160.00K | 575.00K |
| Investing Cash Flow | -32.70M | 1.15B | 124.49M | 10.72M | -83.05M | 176.71M | -56.33M | -148.24M | 111.04M | -106.25M | -2.63M | -2.43M | -3.05M |
| Debt Repayment | n/a | -631.60M | -10.73M | 144.65M | -2.15M | 229.44M | n/a | 222.50M | n/a | n/a | n/a | -69.00K | -206.00K |
| Common Stock Repurchased | -199.55M | -132.28M | -9.06M | -9.75M | -3.17M | -9.81M | -8.56M | -3.87M | -756.00K | -178.00K | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 618.00K | 5.08M | 3.47M | -11.73M | 3.44M | 5.57M | 10.22M | 7.57M | 3.05M | 370.80M | 123.59M | 121.61M | 86.69M |
| Financial Cash Flow | -198.93M | -758.81M | 91.86M | 263.08M | 1.29M | 225.20M | 1.66M | 479.23M | 81.31M | 370.62M | 123.59M | 121.54M | 86.48M |
| Net Cash Flow | -258.63M | 208.21M | 8.50M | 23.40M | -319.96M | 289.04M | -255.73M | 232.00M | 23.49M | 370.62M | n/a | n/a | n/a |
| Free Cash Flow | -29.48M | -187.56M | -211.26M | -257.02M | -241.37M | -120.11M | -203.46M | -101.12M | -171.50M | -178.26M | -123.69M | -121.70M | -87.06M |